As development moves towards combination and sequencing strategies, trial design must also clarify whether the objective is to establish the value of a regimen or the incremental contribution of an individual component. Choices around background therapy, co-initiation versus add-on design, comparators, rescue rules and Estimands should be made accordingly, with benefit interpreted against the additional safety, treatment burden and cost that combination treatment may bring (Solitano et al, 2025).